Skip to main content
Clinical Trials/RBR-3k6982
RBR-3k6982
Not yet recruiting
未知

Assessment of primary skin irritability,accumulation and awareness of products forthrough the contact test.

Makelab Consultoria Eireli0 sitesJune 3, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Makelab Consultoria Eireli
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 3, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Makelab Consultoria Eireli

Eligibility Criteria

Inclusion Criteria

  • Women; Age: 18 to 65 years; Phototype: I to IV; Whole skin of the region; Occasional user of products of the category

Exclusion Criteria

  • Participants who refuse to participate in the study in question; Skin marks in the experimental area that interfere in the evaluation of possible skin reactions; Active dermatoses (local and disseminated) that may interfere with the results of the study; Pregnant or lactating women; History of allergic reactions, irritation or intense feelings of discomfort to topical products: cosmetics and medicines; Volunteers with a history of allergy to the material used in the study; Background of atopy; Use of vaginal cream; Participants with a history of allergy to products in the tested category; Recent gynecological surgeries; Discharges; History of pathologies aggravated or triggered by ultraviolet radiation; Immunodeficiency sufferers; Kidney, heart or liver transplantation; Forecast of intense sun exposure or tanning session during the period
  • conducting the study; Forecast of bathing in the sea, pool or sauna during the study; Participants who practice water sports; Use of the following medications for systemic topical use: immunosuppressants, antihistamines, non\-hormonal anti\-inflammatory drugs, and corticosteroids up to two weeks before selection; Treatment with acidic vitamin A and / or its derivatives orally or topically up to 01 month before the beginning of the study; Vaccination forecast during the study or up to 03 weeks before the study; Any condition not mentioned above that, in the opinion of the investigator, could compromise the evaluation of the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials